Breaking News, Collaborations & Alliances

Merck, NewLink Genetics In Ebola Vax Pact

Aims to develop, manufacture, and distribute NewLink's rVSV-EBOV candidate

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Merck and NewLink Genetics Corp. have entered an exclusive worldwide license agreement to research, develop, manufacture, and distribute NewLink’s investigational rVSV-EBOV Ebola vaccine candidate.   Originally developed by the Public Health Agency of Canada (PHAC), rVSV-EBOV is currently in Phase I trials. Pending the results, the U.S. National Institutes of Health (NIH) plans to initiate a large randomized Phase III study in early 2015 to evaluate rVSV-EBOV vaccine and another investigat...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters